Rockwell Automation Showcases Emulate3D Factory Test for the First Time at NVIDIA GTC 2025
Rockwell Automation (NYSE:ROK), the world’s largest company dedicated to industrial automation and digital transformation, will debut its new Emulate3D® Factory Test™ capabilities at NVIDIA GTC 2025. This first public showcase will demonstrate how the solution enables factory-scale virtual controls testing, helping manufacturers conduct Factory Acceptance Testing to validate automation systems before deployment. Attendees will get an exclusive look at how Factory Test, integrated with NVIDIA Omniverse™ APIs and OpenUSD, is redefining digital twin technology with high-fidelity simulation and real-time collaboration.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250313584308/en/
Rockwell Automation Showcases Emulate3D Factory Test for the First Time at NVIDIA GTC 2025. (Photo: Business Wire)
“Manufacturers need scalable, high-fidelity digital twins to optimize system performance and accelerate commissioning times,” said Matheus Bulho, senior vice president, software and control, Rockwell Automation. “With the launch of Emulate3D Factory Test, we’re providing a solution that allows engineering teams to test, iterate and validate automation systems at full factory scale – leveraging the power of NVIDIA Omniverse to deliver unprecedented visualization and collaboration capabilities.”
Factories are inherently complex environments, with thousands of moving parts, high-speed machinery and intricate system interactions. Traditional simulation tools often struggle to model these environments with sufficient fidelity and scale. Factory Test overcomes these challenges with a modular modeling approach, enabling teams to build, verify and combine mechanical, electrical, controls, process, robotics and device behavior models into a unified digital twin.
At launch, Emulate3D Factory Test will introduce key capabilities, including:
- Multi-model orchestration – Synchronizing multiple system models for factory-scale testing
- Modern DevOps workflows – Streamlining version control, testing and deployment while allowing all stakeholders to work from the latest version, track changes in real time and maintain alignment across teams
- Test Runner – Enabling repeatable, automated testing at scale
- Fault Framework – Simulating fault conditions to assess system resilience
- Advanced full-factory visualization – Powered by NVIDIA Omniverse APIs, initially available via private preview.
“NVIDIA Omniverse and OpenUSD are redefining how industries use AI-driven simulation to optimize design and operations,” said Brian Harrison, senior director of Omniverse Digital Twins at NVIDIA. “With Emulate3D Factory Test, Rockwell Automation is integrating Omniverse technologies and OpenUSD to bring next-generation digital twins to the industrial sector, helping teams simulate, validate and optimize complex manufacturing systems at an unprecedented scale.”
The debut of Factory Test coincides with NVIDIA GTC 2025, held March 17-21 in San Jose, Calif. As part of the event, Rockwell Automation experts will present “Exploring Factory-Scale Digital Twin Simulation with Rockwell Automation” on March 20 at 11 a.m. PDT. This session will showcase how Emulate3D Factory Test, with advanced capabilities enabled by NVIDIA Omniverse APIs, is transforming industrial automation through AI-driven simulation and digital twin technology.
This announcement builds upon Rockwell’s November 2024 announcement, which introduced the collaboration with NVIDIA to bring AI and physics-based simulation to industrial automation. The introduction of Factory Test represents another milestone in the journey toward more intelligent, autonomous operations.
Click here to learn more about Emulate3D Factory Test.
About Rockwell Automation
Rockwell Automation, Inc. (NYSE: ROK), is a global leader in industrial automation and digital transformation. We connect the imaginations of people with the potential of technology to expand what is humanly possible, making the world more productive and more sustainable. Headquartered in Milwaukee, Wisconsin, Rockwell Automation employs approximately 27,000 problem solvers dedicated to our customers in more than 100 countries as of fiscal year end 2024. To learn more about how we are bringing the Connected Enterprise to life across industrial enterprises, visit www.rockwellautomation.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20250313584308/en/
Contacts
Media contact:
Chaya Jacobs
Director, Media & Social
Rockwell Automation
414-305-2784
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
SINOVAC Announces Record and Distribution Dates for Special Cash Dividend30.4.2025 09:00:00 EEST | Press release
Sinovac Biotech Ltd. (NASDAQ: SVA) (“SINOVAC” or the “Company”), a leading provider of biopharmaceutical products in China, today announced that a special dividend of US$55.00 per common share, as previously announced on April 1, 2025, will be paid in cash to valid holders of SINOVAC’s common shares as of the close of business on May 23, 2025, ET. Such cash dividend is expected to be paid on or about July 9, 2025. About SINOVAC Sinovac Biotech Ltd. (SINOVAC) is a China-based biopharmaceutical company that focuses on the R&D, manufacturing, and commercialization of vaccines that protect against human infectious diseases. SINOVAC’s product portfolio includes vaccines against COVID-19, enterovirus 71 (EV71) infected hand-foot-mouth disease (HFMD), hepatitis A, varicella, influenza, poliomyelitis, pneumococcal disease, etc. The COVID-19 vaccine, CoronaVac®, has been approved for use in more than 60 countries and regions worldwide. The hepatitis A vaccine, Healive®, passed WHO prequalificat
SES: Q1 2025 Results30.4.2025 08:30:00 EEST | Press release
SES S.A. announces financial results for the three months ended 31 March 2025. Revenue of €509 million (-0.5% yoy(1)) and Adjusted EBITDA(2) of €280 million (-0.9% yoy(1)), both growing excl. periodic impact Networks revenue up +8.4% yoy(1) including some periodic impact supported by growth in Government (+13.1% yoy(1)) and Mobility (+8.5% yoy(1)); Media (-10.6% yoy(1)) in-line with expectations €360 million of new business and contract renewals signed in Q1 2025 Net Leverage at 1.2x(3) (including cash & cash equivalents of €3.1 billion(4)) O3b mPOWER satellites 7&8 have reached final orbital position – boosting mPower network capacity and resilience from May FY 2025 financial outlook(5) on track with yoy stable Revenue and broadly stable Adjusted EBITDA re-affirmed Fully funded Intelsat acquisition anticipated to complete in H2 2025 – intention to optimise the combined debt structure On 3 April 2025, AGM approved all company recommended resolutions including prioritisation of sharehol
Geoswift Launches Visa Direct to Enhance Cross-Border Payment Offers in Over 30 Countries30.4.2025 04:00:00 EEST | Press release
Geoswift announced today the integration of Visa Direct with Geoswift's cross-border payments platform. Visa Direct facilitates payouts to more than 140 countries and territories. The integration will enable payouts in 32 countries and territories, across 13 currencies, covering major markets in Asia Pacific, North America, Europe and Middle East, with plans for more in the future. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250423288249/en/ Bryan Ma, SVP, Head of Geoswift Global Payments, and Swapnil Mhasde, Head of Visa Direct Commercialization and Solutions, Asia Pacific, celebrating the launch in Singapore. Geoswift is a leading provider of cross-border payment services and solutions globally. With over two decades of innovation, it has become a trusted name in B2B, education, eCommerce, remittance, and travel payment use cases. Raymond Qu, Group CEO of Geoswift, stated, "At Geoswift, our vision has always been to del
Logitech Announces Q4 and Full Fiscal Year 2025 Results29.4.2025 23:03:00 EEST | Press release
SIX Swiss Exchange Ad hoc announcement pursuant to Art. 53 LR — Logitech International (SIX: LOGN) (Nasdaq: LOGI) today announced financial results for the fourth quarter and full Fiscal Year 2025 ended March 31, 2025. For Fiscal Year 2025: Sales were $4.55 billion, up 6 percent in US dollars and 7 percent in constant currency, compared to the prior year. GAAP operating income was $655 million, up 11 percent compared to the prior year. Non-GAAP operating income was $775 million, up 11 percent compared to the prior year. GAAP earnings per share (EPS) was $4.13, up 7 percent compared to the prior year. Non-GAAP EPS was $4.84, up 14 percent compared to the prior year. Cash flow from operations was $843 million. The year-ending cash balance was $1.5 billion. The Company returned $797 million of cash to shareholders through its annual dividend payment and share repurchases. For Q4 Fiscal Year 2025: Sales were $1.01 billion, flat in US dollars and up 2 percent in constant currency, compared
U.S. Patent and Trademark Office Invalidates Pharmacyclics Patent Asserted Against BeiGene29.4.2025 22:32:00 EEST | Press release
BeiGene, Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company that intends to change its name to BeOne Medicines Ltd., today announced that the U.S. Patent and Trademark Office (USPTO) rendered a Final Written Decision invalidating all claims of Pharmacyclics LLC’s (Pharmacyclics) U.S. Patent No. 11,672,803 (the ‘803 patent) that were challenged by BeiGene in a post-grant review (PGR) proceeding. On November 1, 2023, BeiGene filed a PGR petition with the USPTO challenging the validity of certain claims of the ‘803 patent, in response to a patent infringement lawsuit Pharmacyclics brought against BeiGene concerning BRUKINSA® (zanubrutinib). On May 1, 2024, the USPTO granted BeiGene’s petition to institute the PGR. The USPTO’s Final Written Decision is appealable by Pharmacyclics. Commenting on the ruling, BeiGene General Counsel Chan Lee said: “We are pleased that the USPTO invalidated all challenged claims of the ‘803 patent. Today’s decision reinforces our belief th
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom